Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections

References

• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017 Feb 15;215(suppl_1):S28–s36.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012 Oct;55(7):943–950.
   PubMed Web of Science ®Google Scholar
• Cassini A, Hogberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56–66.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011 Oct;17(10):1791–1798.
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013 Sep;13(9):785–796.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, et al. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31:2.
   Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017 Jul;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015 Jul;70(7):2133–2143.
   PubMed Web of Science ®Google Scholar
• Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266–271.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835–1846.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Rhomberg PR, Flamm RK, et al. Effect of the beta-Lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Sep;60(9):5454–5458.
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Alharbi A, Alshehri S, et al. Plazomicin: a novel aminoglycoside for the treatment of resistant gram-negative bacterial infections. Drugs. 2019 Feb;79(3):243–269.
   PubMed Web of Science ®Google Scholar
• Galani I, Nafplioti K, Adamou P, et al. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. BMC Infect Dis. 2019 Feb 15;19(1):167.
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother. 2011 Jan;66(1):48–53.
   PubMed Web of Science ®Google Scholar
• Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents.  2019 Feb;53(2):177–184.
   Web of Science ®Google Scholar
• Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774–1778.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Kazmierczak K, Bouchillon SK, et al. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother. 2015 Jul;59(7):4239–4248.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a kpc-3-expressing klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59:6605–6607.
   Google Scholar
• Shields RK, Clancy CJ, Hao B, et al. Effects of klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant k. Pneumoniae. Antimicrob Agents Chemother. 2015;59:5793–5797.
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clinical Infectious Diseases: An Official Publication of The Infectious Diseases Society of America. 2016;63:1615–1618.
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant klebsiella pneumoniae infections. Antimicrob agents chemother. 2017; 61.
   Google Scholar
• Gaibani P, Campoli C, Lewis RE, et al. In vivo evolution of resistant subpopulations of kpc-producing klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73:1525–1529.
   Google Scholar
• Sun D, Rubio-Aparicio D, Nelson K, et al. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017;61(12):Dec.
   Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018 Dec;7(4):439–455.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against beta-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE). J Antimicrob Chemother. 2017 Oct 1;72(10):2792–2795.
   PubMed Web of Science ®Google Scholar
• Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient–concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014 Nov;20(77):3–11.
   Google Scholar
• Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008 Sep 15;47(Suppl 1):S32–40.
   PubMed Web of Science ®Google Scholar
• Ong CT, Tessier PR, Li C, et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis. 2007 Feb;57(2):153–161.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock–does the dose matter? Crit Care. 2009;13(3):214.
   PubMed Web of Science ®Google Scholar
• Wong G, Brinkman A, Benefield RJ, et al. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014 May;69(5):1416–1423.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012 Dec;56(12):6343–6348.
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang KT, Zhou J, et al. Determining beta-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 May 1;72(5):1421–1428.
   PubMed Web of Science ®Google Scholar
• Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006 Feb;40(2):219–223.
   PubMed Web of Science ®Google Scholar
• Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012 Jun 28;16(3):R113.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent beta-Lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681–691.
   PubMed Web of Science ®Google Scholar
• Vourli S, Tsala M, Kotsakis S, et al. Comparison of short versus prolonged infusion of standard dose of meropenem against carbapenemase-producing Klebsiella pneumoniae isolates in different patient groups: a pharmacokinetic-pharmacodynamic approach. J Pharm Sci. 2016 Apr;105(4):1513–1518.
   PubMed Web of Science ®Google Scholar
• Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother. 2013 Mar;68(3):490–491.
   PubMed Web of Science ®Google Scholar
• Ho VP, Jenkins SG, Afaneh CI, et al. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect (Larchmt). 2011 Aug;12(4):325–327.
   PubMed Web of Science ®Google Scholar
• Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014 May;58(10):1439–1448.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother. 2010 Jun;65(6):1119–1125.
   PubMed Web of Science ®Google Scholar
• Del Bono V, Giacobbe DR, Marchese A, et al. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox? Virulence. 2017 Jan 2;8(1):66–73.
   PubMed Web of Science ®Google Scholar
• Pea F, Della Siega P, Cojutti P, et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? Int J Antimicrob Agents. 2017 Feb;49(2):255–258.
   PubMed Web of Science ®Google Scholar
• Hawkey PM, Warren RE, Livermore DM, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2–iii78.
   PubMedGoogle Scholar
• Cojutti P, Sartor A, Righi E, et al. Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to kpc-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2017 Oct;61(10).
   Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011 Aug;17(8):1135–1141.
   PubMed Web of Science ®Google Scholar
• Giannella M, Trecarichi EM, Giacobbe DR, et al. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2018 Feb;51(2):244–248.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A, Souli M, et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther. 2012 Dec;10(12):1393–1404.
   PubMed Web of Science ®Google Scholar
• Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014 Sep;69(9):2305–2309.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis. 2006 Jun 15;42(12):1764–1771.
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Ma B, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48(9):575–584.
   PubMed Web of Science ®Google Scholar
• van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015 Apr;70(4):1203–1211.
   PubMed Web of Science ®Google Scholar
• Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother. 2018 Apr 1;73(4):1104–1106.
   PubMed Web of Science ®Google Scholar
• Slama TG. Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use. Crit Care. 2008;12(5):233.
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens P, Rubinstein E. Adverse reactions to beta-lactam antimicrobials. Expert Opin Drug Saf. 2012 May;11(3):381–399.
   PubMed Web of Science ®Google Scholar
• McDonald C, Cotta MO, Little PJ, et al. Is high-dose beta-lactam therapy associated with excessive drug toxicity in critically ill patients? Minerva Anestesiol. 2016 Sep;82(9):957–965.
   PubMed Web of Science ®Google Scholar
• Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017 Oct 1;72(10):2891–2897.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Jezek A, Murray BE, et al. The infectious diseases society of America’s 10 x ‘20 Initiative (10 new systemic antibacterial agents US food and drug administration approved by 2020): is 20 x ‘20 a possibility? Clin Infect Dis. 2019 Jun 18;69(1):1–11.
   PubMed Web of Science ®Google Scholar